tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

LifeTech Scientific Reports Mixed Interim Results Amidst Increased Expenses

Story Highlights
LifeTech Scientific Reports Mixed Interim Results Amidst Increased Expenses

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from LifeTech Scientific Corporation ( (HK:1302) ).

LifeTech Scientific Corporation announced its interim results for the six months ending June 30, 2025, reporting a turnover of approximately RMB676.7 million, a 3.7% increase from the previous year. However, the company’s net profit, after accounting for non-recurring items, saw a significant decrease of 73.2% compared to the same period in 2024, primarily due to changes in financial asset gains and increased share-based payment expenses.

The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

More about LifeTech Scientific Corporation

LifeTech Scientific Corporation is a company incorporated in the Cayman Islands, operating in the medical technology industry. It focuses on developing and providing medical devices and solutions, particularly in the area of cardiovascular and peripheral vascular diseases.

Average Trading Volume: 43,927,223

Technical Sentiment Signal: Hold

Current Market Cap: HK$8.85B

Find detailed analytics on 1302 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1